Retention in care and virological failure among adult HIV+ patients on second-line ART in Rwanda: a national representative study

Sabin Nsanzimana1,2,3*, Muhammed Semakula1, Vedaste Ndahindwa4, Eric Remera1, Dieudonne Sebuhoro1, Jean Paul Uwizihwe1, Nathan Ford5, Marcel Tanner3, Steve Kanters6, Edward J. Mills7 and Heiner C. Bucher2

Abstract

Background: Currently, there is limited evidence on the effectiveness of second-line antiretroviral therapy (ART) in sub-Saharan Africa. To address this challenge, outcomes of second-line protease inhibitor (PI) based ART in Rwanda were assessed.

Methods: A two-stage cluster sampling design was undertaken. 49 of 340 health facilities linked to the open-source electronic medical record (EMR) system of Rwanda were randomly sampled. Data sampling criteria included adult HIV positive patients with documented change from first to second-line ART regimen. Retention in care and treatment failure (viral load above 1000 copies/mL) were evaluated using multivariable Cox proportional hazards and logistic regression models.

Results: A total of 1688 patients (60% females) initiated second-line ART PI-based regimen by 31st December 2016 with a median follow-up time of 26 months (IQR 24–36). Overall, 92.5% of patients were retained in care; 83% achieved VL ≤ 1000 copies/ml, 2.8% were lost to care and 2.2% died. Defaulting from care was associated with more recent initiation of ART- PI based regimen, CD4 cell count ≤500 cells/mm³ at initiation of second line ART and viral load > 1000 copies/ml at last measurement. Viral failure was associated with younger age, WHO stage III&IV at ART initiation, CD4 cell count ≤500 cells/mm³ at switch, atazanavir based second-line ART and receiving care at a health center compared to hospital settings.

Conclusions: A high proportion of patients on second-line ART are doing relatively well in Rwanda and retained in care with low viral failure rates. However, enhanced understandings of adherence and adherence interventions for less healthy individuals are required. Routine viral load measurement and tracing of loss to follow-up is fundamental in resource limited settings, especially among less healthy patients.

Keywords: HIV, Second-line antiretroviral therapy, Treatment failure
Background

According to the 2016 estimates of the Joint United Nations Programme on HIV/AIDS (UNAIDS), 36.7 million people lived with HIV globally, and approximately half were on antiretroviral therapy (ART) [1, 2]. Sub-Saharan Africa (SSA), in particular, accounts for more than 80% of the global population of people living with HIV (PLHIV) [3]. Since the introduction of ART in 1996, there have been substantial declines in morbidity and mortality related to HIV [3, 4]. Despite this achievement, a considerable number of people have failed to maintain a sustained virological and immunological response to ART [5].

The World Health Organization (WHO) recommends the use of a two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) backbone and a non-nucleoside/nucleotide reverse transcriptase inhibitor (NNRTI) as a first-line ART; The proposed switch to a second-line regimen comprises of a ritonavir-boosted protease inhibitor (PI/r) with two NRTIs [6]. The number of PLHIV switching from first- to second-line ART regimens is increasing and this shift is related to several factors. Primarily, non-adherence to medication, as a result of adverse events or non-continuous medication access was reported in many studies as the key cause of treatment failure [7]. Additionally, as ART scale-up in SSA and elsewhere was initiated in 2004 [3, 4], more PLHIV began receiving treatment. Unavoidably, even under optimal circumstances, treatment failures will occur overtime, resulting in an increase in the number of individuals in requiring second-line ART. Other factors, such as increased resistance testing, improved adverse events detection and enhanced country access to affordable medications will also likely contribute to improved accessibility to second-line ART [4].

Since the launch of second-line regimens in SSA, outcomes of large-scale national ART programmes were assessed only in a few studies [8–13]. Botswana and Rwanda are two countries in SSA achieving the highest ART coverage >80% [1, 2]. Of the estimated 220,000 PLHIV in Rwanda, 175,398 (80%) were receiving ART by December 2016 [9]. Rwanda, for example, has demonstrated a high rate of patients on first-line ART (>90%) [14]. Similarly, the number of patients on second-line ART in Rwanda has also increased substantially in the last decade from 388 patients in 2007 to 7625 by the end of December 2016, representing ~4% of all patients on ART. Given this progress, the purpose of this study is to assess the outcomes associated with the rapid expansion of second-line ART access in Rwanda [15].

Methods

Study design and data sources

By the end of 2016, a total of 553 health facilities were offering HIV treatment in Rwanda. Among them, 513 had enrolled 7625 patients on second-line ART. Since the open-source electronic medical record (EMR) system was available in only 340 of the 553 health facilities, this constituted our sampling frame. A two-stage cluster sampling design was undertaken to randomly select 49 of the 340 eligible sites where all patients were considered for analysis in a retrospective observational cohort study using routinely collected program data.

A comprehensive list of health facilities providing second-line ART in Rwanda was compiled using the Health Management Information data hosted at the Rwanda Biomedical Center. This list formed the basis of our first sampling frame, which consisted of our randomly selected sample of health facilities. We restricted our selection to health facilities that had a fully functioning EMR system. There were no other expected differences with health facilities that were in the process of EMR roll out. Our stratification was balanced, enabling equal opportunity for the inclusion of urban, rural, small and big sites.

Our data source consists of electronic medical records. After selecting 49 sites, we determined the data sampling criteria to include all adult patients (aged 15 years or older) on second-line ART. The total number of patient data used for the study was 1689, representing about 25% of the total patients on second-line regimen in Rwanda. We excluded from our analysis all patients who had switched to third line ART. Since Rwanda is currently in the process of transferring HIV related data sources to a national electronic database, some data are still stored locally. Two authors DS and VN visited all 49 health facilities and extracted data backups from EMR local servers using **mysql** software and exported them to STATA version 14 to conduct the analyses.

Study population and definitions

Our study included patients aged 15 years or older, who switched to second-line ART in 49 randomly selected health facilities in Rwanda since the start of second line program in 2004 until 31st December 2016.

First-line ART regimens were composed of one NNRTI plus two NRTIs and second-line regimens were PI-based, in accordance with national guidelines. Two key possible reasons for change may be due to first-line treatment failure (virological and/or immunological) or the result of adverse-effects to any compound in first-line combinations or prior exposure to antiretroviral drugs. The frequency of CD4 cell count measurement was bi-annual while viral load has been measured annually for most of patients according to the national guidelines except in exceptional circumstances guided by decision from individual clinician.

We defined **virological failure** as having a viral load (VL) > 1000 copies/mL after at least 12 months on
second-line ART with self-reported good adherence to medication (> 90% no dose missed). Viral load failure was used as an approach to confirm treatment failure. The VL suppression threshold of ≤1000 copies/mL and undetectable VL ≤20 copies/mL were in accordance with the 2016 WHO consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection [6].

We defined retention as alive and in care on second-line ART at the time of data collection (31st December 2016) and with no met criteria for loss to follow-up (having missed contact with the health facility during 3 consecutive months). Deaths were assessed using recorded medical data in the EMR, which included deaths that occurred outside of the health facilities. Deaths were recorded within the national mortality registry. Both viral suppression and loss to care served as the outcomes. The explanatory variables for this analysis were all measured at time of switch from first to second line ART and included demographic variables (age, sex, marital status, body mass index (BMI), clinical variables (TB screening status, CD4 cell count, WHO stage, viral load, date of ART initiation, type of ART regimen), and health facility-level variables (type of health facility: district hospitals, health centers and referral hospitals).

Statistical analyses
Data are presented as medians and interquartile ranges (IQRs) for continuous variables and frequencies and percentages for categorical variables. Fisher’s exact test was used to assess the association between outcome of interest (retention and viral load suppression) and each predictor. We used multivariate Cox proportional-hazards regression to analyze time to discontinuation (loss to follow-up or death) on second-line ART. The regression model included the following covariates: age, gender, CD4 cell count strata, WHO clinical stage, ART regimen, viral load, and type of health facilities at the time of first ART. The overall dataset contained only one case of missing value which was not considered for retention outcome. We controlled all different antiretroviral backbones and PI based combinations for each individual patient to assess differences in ART formulations vis-à-vis retention and viral suppression.

The proportional hazard model test was used to ensure that the proportional assumption was met. For model selection, we used Aikaike Information Criteria (AIC) to identify the model that best-balanced parsimony and minimized residuals.

To model virological suppression, multiple logistic regression was used to analyze viral load suppression using the latest viral measurements. Finally, we calculated the probability of a subject not being suppressed given a set of predictors in order to obtain adjusted coefficients. The coefficients were expressed as adjusted odds ratios (OR). The model diagnostics were performed to assess the goodness of fit using Hosmer and Lemeshow test, deviance, and Pearson’s Statistics. All analyses were conducted using STATA statistical software, version 14.

Ethical approval
Data used for this study were anonymized, de-identified and routinely collected programme data maintained by the Rwanda Biomedical Centre, Division of HIV/AIDS, STIs and Other Blood Borne Infections. No participants were involved directly in the data collection therefore their consent was waived by the Rwanda National Ethics Committee which also approved the use of routine programme data presented here. The Rwanda Ministry of Health also granted approval for data access and use to the principal investigator (SN) for the purposes of improving programme performance in Rwanda.

Results
Among the 181,921 individuals on ART in Rwanda [9], 174,252 (95.8%) received first-line ART and 7625 (4.2%) received second-line ART by 31st December 2016 while 44 patients were on third line ART [16]. Figure 1 presents a flow diagram of the second line ART Rwanda study sites and the patient selection process.

In our analysis, 1688 eligible patients were included, all of which had initiated second-line ART in 49 randomly selected health facilities representing about 25% of all patients on second-line ART nationwide. Table 1 presents the baseline characteristics of the selected patients. There were more women (60%) in the sample.

The median age range was 35–44 years and approximately 38% of patients had initiated ART at WHO stage 3 or 4. The majority of patients (64%) had initiated second-line ART prior to 2010 resulting in median follow-up time of 26 months (IQR 24–36).

In total, 1562/1688 (92.5%) individuals were retained in care, 126 (7.5%) were lost to follow-up (5.2%) or had died (2.2%). Retention appeared to be lowest among those aged 25–34 years, who were single, and the least healthy. Retention was 89.0% in individuals who were underweight and 90.7% among patients screened positive for tuberculosis, and 90.4% among those with CD4 cell counts below 350 cells/mm<sup>3</sup> at initiation of ART.

In all 1688 individuals, at least one viral load result was available, regardless of whether patients had subsequently defaulted from care. Of these, 1387 of 1688 (83%) individuals were virologically suppressed (≤1000 copies/mL) at last follow-up, whereas 1056 (63%) achieved undetectable viral loads (≤20 copies/mL). Virological failure with VL > 1000 copies/mL was found in 301 of 1689 (18%) individuals. Of all those retained in
care, a higher proportion were virologically undetectable at the time of the last available viral load test result compared to those lost to care (64% vs 43%). Virological failure was also higher among those who were lost to care (35% vs 16%). Retention in care was 94% for those who were virologically suppressed and 85% for those who were not suppressed.

Hazard for defaulting from care
The predictors of defaulting from care are presented in Table 2.

These included ART initiation period from 2010 to 2012 and from 2013 to 2016 relative to 2009 or earlier (adjusted hazard ratios [HR] 2.43, 95% confidence interval [CI] 1.47–4.01 and HR 2.49, 95% CI 1.00–6.18), CD4 cell count ≤500 cells/mm³ vs CD4 cell count > 500 cells/mm³ at initiation (HR 2.12, 95% CI 1.20–3.75), lopinavir/ritonavir (LPV/r) vs. atazanavir/ritonavir (ATV/r) based second-line regimen (HR 1.91, 95% CI 1.08–3.40) and viral load > 1000 copies/ml vs. CD4 count > 500 cells/mm³ at ART initiation (HR 5.40, 95% CI: 3.75–7.77), WHO stage III & IV care compared to WHO stage I and II at programme enrollment (OR, 1.56, 95% CI 1.18–2.06), ATV/r compared to LPV/r based second-line regimen (OR 1.48, 95% CI 1.12–1.95) and receiving care at a health center relative to regional or provincial hospital (OR 1.55, 95% CI 1.11–2.17).

Risk factors for virological failure
The following risk factors were associated with virological failure in multivariate analysis: Age groups 15–29 years and 30–39 years compared to age group 40–59 years (adjusted odds ratios (OR): 2.22, 95% CI 1.46–3.38 and OR 1.45, 95% CI 1.03–2.05), CD4 cell count ≤500 cells/mm³ vs. CD4 count > 500 cells/mm³ at ART initiation (OR 5.40, 95% CI: 3.75–7.77), WHO stage III & IV care compared to WHO stage I and II at programme enrollment (OR, 1.56, 95% CI 1.18–2.06), ATV/r compared to LPV/r based second-line regimen (OR 1.48, 95% CI 1.12–1.95) and receiving care at a health center relative to regional or provincial hospital (OR 1.55, 95% CI 1.11–2.17).

Discussion
Our study is the first to report on retention and viral load outcomes using a national representative sample of second-line ART patients in Rwanda. We found that, overall, a high proportion of patients were retained in care after a median follow-up of 26 months. The estimated 92.5% retention was higher than that reported in previous studies in similar settings [10, 17]. High retention in care in the Rwanda HIV programme was also previously reported [9, 18]. Several possible reasons for high rates of retention in care include the highly decentralized health system that provides easy to access HIV
Table 1  Baseline characteristics of patients on second-line ART in Rwanda stratified by retention and viral suppression

| Characteristics                  | Total   | Retained | Defaulting from care | Viral load suppression (copies/ml) |
|----------------------------------|---------|----------|----------------------|-----------------------------------|
|                                  | n (%)   | Alive    | LTFU     | Died | ≤ 1000 | > 1000 |
| Median age (IQR)                 | 41 (33, 49) |          |          |      |        |        |
| Age category (year)              |         |          |          |      |        |        |
| 15–29                            | 327 (19) | 300 (92) | 24 (7)   | 3 (1) | 327 (19) | 242 (74) | 85 (26) |
| 30–39                            | 426 (25) | 390 (92) | 28 (7)   | 8 (2) | 426 (25) | 344 (81) | 82 (19) |
| 40–59                            | 841 (50) | 785 (93) | 35 (4)   | 21 (2) | 842 (50) | 718 (85) | 124 (15) |
| 60+                              | 94 (6)   | 87 (93)  | 2 (2)    | 5 (5) | 94 (6)   | 84 (89)  | 10 (11)  |
| Total                            | 1688 (100) | 1562 (93) | 89 (5)   | 37 (2) | 1689 (100) | 1388 (82) | 301 (18) |
| Sex                              |         |          |          |      |        |        |
| Female                           | 1031 (61) |          |          |      |        |        |
| Male                             | 657 (39)  |          |          |      |        |        |
| Total                            | 1688 (100) | 1562 (93) | 89 (5)   | 37 (2) | 1689 (100) | 1388 (82) | 301 (18) |
| Marital status                   |         |          |          |      |        |        |
| Single                           | 344 (20)  |          |          |      |        |        |
| Married/Cohabitating             | 648 (38)  |          |          |      |        |        |
| separated/Divorced               | 98 (6)    |          |          |      |        |        |
| Widowed                          | 226 (13)  |          |          |      |        |        |
| Missing                          | 372 (22)  |          |          |      |        |        |
| Total                            | 1688 (100) | 1562 (93) | 89 (5)   | 37 (2) | 1689 (100) | 1388 (82) | 301 (18) |
| ART Initiation period            |         |          |          |      |        |        |
| 2009 and before                  | 1062 (63) |          |          |      |        |        |
| 2010–2012                        | 502 (30)  |          |          |      |        |        |
| 2013–2016                        | 123 (7)   |          |          |      |        |        |
| Total                            | 1687 (100) | 1561 (93) | 89 (5)   | 37 (2) | 1688 (100) | 1388 (82) | 300 (18) |
| TB Screening                     |         |          |          |      |        |        |
| Negative                         | 1458 (86) |          |          |      |        |        |
| Positive                         | 151 (9)   |          |          |      |        |        |
| N/A                              | 79 (5)    |          |          |      |        |        |
| Total                            | 1688 (100) | 1562 (93) | 89 (5)   | 37 (2) | 1689 (100) | 1388 (82) | 301 (18) |
| Body mass index                  |         |          |          |      |        |        |
| Normal weight                    | 964 (57)  |          |          |      |        |        |
| Underweight                      | 186 (11)  |          |          |      |        |        |
| overweight & Obese               | 538 (32)  |          |          |      |        |        |
| Total                            | 1688 (100) | 1562 (93) | 89 (5)   | 37 (2) | 1689 (100) | 1388 (82) | 301 (18) |
| Median CD4 (IQR)                 | 418 (248, 618) |          |          |      |        |        |
| > 500 cells/mm³                  | 638 (38)  |          |          |      |        |        |
| ≤ 500 cells/mm³                  | 1050 (62) |          |          |      |        |        |
| Total                            | 1688 (100) | 1562 (93) | 89 (5)   | 37 (2) | 1689 (100) | 1388 (82) | 301 (18) |
| WHO stage                        |         |          |          |      |        |        |
| Stage 1–2                        | 1042 (62) |          |          |      |        |        |
| Stage 3–4                        | 623 (37)  |          |          |      |        |        |
| missing                          | 23 (1)    |          |          |      |        |        |
| Total                            | 1688 (100) | 1562 (93) | 89 (5)   | 37 (2) | 1689 (100) | 1388 (82) | 301 (18) |
services (98% of health facilities in Rwanda offer integrated, comprehensive HIV services). Further, there is a strong network of PLHIV that supports peer adherence to medication including home visits, awareness and education activities in the communities. In addition, Rwanda has a robust electronic monitoring and surveillance system that allows early warning signs of lost to care, which initiates home visits by health care providers. Finally, health care seeking behavior in the Rwandan PLHIV population is high [9].

Our study identified key factors associated with defaulting from care: initiating at higher viral loads, low CD4 cell count, less clinical engagement, and time of treatment switch. Other studies from SSA and Asia have investigated predictors of attrition in care [10, 19–22]. Across many settings, loss to follow-up on second-line patients was significantly higher among those with low CD4 cell count at baseline, and previously undiagnosed treatment failure on a first-line regimen [20–29]. Other findings in similar settings reported that advanced disease at initiation was associated with attrition on second-line ART, and is likely the result of mortality [30], as well as higher viral load and age [20]. Studies from Malawi [21], Thailand [22] and South Africa [24] reported that adherence was the major determinant of treatment failure.

In this study, viral suppression rate (VL ≤ 1000 copies/mL) among second-line patients in Rwanda was estimated to be 83%. This rate is consistent with similar results observed in other resource limited settings with an average of 80% viral suppression after 12 months on second-line ART [19, 31]. Results obtained from this study are generally consistent with other studies in developing countries. For example, the pooled proportion of virological failure in a recent systematic review and meta-analysis on second-line ART in low- and middle-income countries was 23.1, 26.7 and 38.0% at 12, 24 and 36 months, respectively [18]. In many settings, virological failure was observed in the first 6 months following second-line ART start [18]. However, the reported results had large variations between studies and comparison of treatment failure might be difficult due to different cut offs used for viral load suppression across countries [32, 33].

Patients who were lost to care were more likely to be viraemic than patients who were retained in care – a finding observed also by others [34]. This has important implications for evaluating progress towards the UNAIDS 90–90-90 targets. For instance, assessing virological suppression (the third 90) only among patient retained in care will overestimate success unless losses to care are taken into account.

In Rwanda, a previous study reported that only 23% of patients presenting virological failure (> 1000 copies/mL) had drug resistance mutations suggestive of third line ART, though 77% with high viral load could still remain on efficacious second-line therapy [18, 35]. This reinforces the need for intensive adherence for patients presenting suboptimal viral load suppression before switching to costly and complicated salvage therapies. The same challenge was also reported in other resource-limited countries [19, 29, 35].

---

**Table 1** Baseline characteristics of patients on second-line ART in Rwanda stratified by retention and viral suppression (Continued)

| Characteristics | Total | Retained | Defaulting from care | Viral load suppression (copies/mL) |
|-----------------|-------|----------|----------------------|----------------------------------|
|                 | n (%) | Alive    | LTFU | Died | ≤ 1000 | > 1000 | n (%) | n (%) | n (%) | n (%) | n (%) |
| Second-line ARV regimen |       |          |      |      |       |       |       |       |       |       |       |
| LPV/r + dual NRTI   | 1097 (65) | 1011 (92) | 55 (5) | 31 (3) | 1098 (65) | 920 (84) | 178 (16) |       |       |       |
| ATV/r + dual NRTI   | 591 (35)  | 551 (93)  | 34 (6) | 6 (1)  | 591 (35)  | 468 (79)  | 123 (21)  |       |       |       |
| Total              | 1688 (100) | 1562 (93) | 89 (5) | 37 (2) | 1689 (100) | 1388 (82) | 301 (18)  |       |       |       |
| Median VL (IQR)    | 20 (20, 100) |       |      |      |       |       |       |       |       |       |
| Viral load results  |       |          |      |      |       |       |       |       |       |       |       |
| ≤ 20 copies/mL     | 1056 (63) | 1002 (95) | 43 (4) | 11 (1) | 1562 (93) | 1305 (84) | 257 (16)  |       |       |       |
| 21–1000 copies/mL  | 331 (20)  | 303 (92)  | 20 (6) | 8 (2)  | 126 (7)  | 82 (65)  | 44 (35)  |       |       |       |
| > 1000 copies/mL   | 301 (18)  | 257 (85)  | 26 (9) | 18 (6) | 1688 (100) | 1387 (82) | 301 (18)  |       |       |       |
| Total              | 1688 (100) | 1562 (93) | 89 (5) | 37 (2) | 1688 (100) | 1387 (82) | 301 (18)  |       |       |       |

VL = viral load, TB = tuberculosis, BMI = body mass index, ART = antiretroviral therapy, WHO = World Health Organization, ATV/r = ritonavir boosted atazanavir, LPV/r = ritonavir boosted lopinavir, NRTI = nucleoside/nucleotide reverse transcriptase inhibitors, IQR = interquartile range, LTFU = lost to follow-up

Nsanzimana et al. BMC Infectious Diseases (2019) 19:312
The HIV programme in Rwanda has made major shifts since 2009, when no new drug classes were available for cases of virological failure [20]. The new recommendation was implemented in 2013, when LPV/r based regimens were replaced by ATV/r based regimens. In our analysis, patients who started anti-retrovirals after 2010 had better retention on ART, yet no better VL outcomes.

For this study, we controlled the distributions of backbones for both LPV/r and ATV/r. There was equal distribution of zidovudine, tenofovir and abacavir for each PI-based combination; lamivudine was maintained.

### Table 2: Predictors of attrition and virological failure on second-line ART

| Predictors                              | Multivariate analysis | Virological failure |
|-----------------------------------------|-----------------------|---------------------|
| Defaulting from care                    | Adjusted hazard ratio (95% CI) | p-value | Adjusted odds ratio (95% CI) | p-value |
| Age category (years). Reference category Age 40–59 a | 0.85 (0.42, 1.71) | 0.654 | 2.22 (1.46, 3.38) | < 0.001 |
| 15–29 years                             | 1.03 (0.58, 1.81) | 0.930 | 1.45 (1.03, 2.05) | 0.032 |
| 30–39 years                             | 1.87 (0.80, 4.38) | 0.147 | 0.74 (0.36, 1.53) | 0.421 |
| Sex a                                   | 0.87 (0.53, 1.43) | 0.585 | 1.07 (0.80, 1.43) | 0.644 |
| Marital status. Reference category single a | 0.48 (0.26, 0.90) | 0.023 | 0.96 (0.64, 1.45) | 0.857 |
| Married/Cohabitating                    | 0.69 (0.24, 1.96) | 0.487 | 0.56 (0.27, 1.14) | 0.110 |
| Separated/Divorced                      | 0.57 (0.24, 1.34) | 0.197 | 0.71 (0.40, 1.26) | 0.242 |
| Widowed                                 | 0.31 (0.15, 0.65) | 0.002 | 1.02 (0.68, 1.54) | 0.916 |
| ART initiation. Reference category 2009 and before a | 2.43 (1.47, 4.01) | 0.001 | 2.49 (1.00, 6.18) | 0.049 |
| TB Screening. Reference category TB negative + | 1.26 (0.64, 2.49) | 0.504 | 1.40 (0.92, 2.13) | 0.017 |
| Positive                                | 3.04 (1.49, 6.22) | 0.002 | 1.01 (0.54, 1.88) | 0.979 |
| Underweight BMI<                        | 1.94 (1.05, 3.57) | 0.034 | 0.99 (0.66, 1.50) | 0.965 |
| Overweight BMI >                        | 1.23 (0.73, 2.06) | 0.432 | 0.80 (0.59, 1.09) | 0.155 |
| ≤ 500 copies vs. > 500 cells/mm³        | 2.12 (1.20, 3.75) | 0.009 | 5.40 (3.75, 7.77) | < 0.001 |
| WHO Stages. Reference category Stage 1–2 a | 1.22 (0.77, 1.96) | 0.390 | 1.56 (1.18, 2.06) | 0.002 |
| Stage 3–4                               | 0.49 (0.06, 3.73) | 0.489 | 1.36 (0.46, 3.99) | 0.574 |
| Missing                                 | 0.52 (0.29, 0.93) | 0.027 | 1.48 (1.12, 1.95) | 0.005 |
| ATV/r + 2 NRTI vs. LPV/r + 2 NRTI       | 2.95 (1.83, 4.76) | 0.001 |
| > 1000 copies/mL vs ≤ 1000 copies/mL    | 0.93 (0.52, 1.65) | 0.799 | 1.55 (1.11, 2.17) | 0.010 |
| Health facility types +                 | 1.23 (0.68, 2.22) | 0.496 | 0.92 (0.63, 1.34) | 0.653 |

* variable measured at initiation of ART, + variable measured at switch to second line ART

CI: confidence interval, DH: district hospital, HC: health centre, PH: provincial hospital, RH: regional hospital, TB: tuberculosis, BMI: body mass index, ART: antiretroviral therapy, WHO: World Health Organization, ATV/r: ritonavir boosted atazanavir, LPV/r: ritonavir boosted lopinavir, NRTI: nucleoside/nucleotide reverse transcriptase inhibitors

BMI categories: underweight ≤ 18.5 kg/m², normal weight = 18.5–24.9 kg/m², overweight & obesity = 25 kg/m² or greater
across all second-line regimens as per national guidelines. Patients treated with ATV/r were significantly more likely to experience virological failure. A recent systematic review of six randomized controlled trials on the comparative efficacy of second-line ART did not find a difference in efficacy between LPV/r or ATV/r plus two NRTIs and LPV/r with raltegravir. Although ATV/r had a greater numerical efficacy compared to LPV/r, differences were not statistically significant [25]. Another study conducted in Uganda [26] compared LPV/r and ATV/r in patients failing first-line ART (2NRTI + 1NNRTI) and confirmed comparable potency and efficacy. Being on LPV/r was twofold associated with defaulting from care, which could be due to the higher pill burden and adverse gastro-intestinal drug reactions associated to LPV/r causing low adherence to medication [36]. A recent study in Malawi among patients receiving ATV/r also reported that bilirubin levels predicted VL failure [27]. ATV/r prescription with related increased bilirubin has been associated with high interpatient disparities with hyperbilirubinemia and jaundice resulting into premature discontinuation of atazanavir and subsequently impact on virological outcome [28].

A major strength of our analyses is the relatively large sample size corresponding to 25% of all people living with HIV on second-line ART in Rwanda. We also used routinely reported data that reflects more precisely the everyday life of patients. In addition, we had few missing data and all our patients had at least one viral load measured in the last 12 months on ART. Data were collected from a diverse population of patients in large, medium and small sites. In addition, we managed to successfully demonstrate how nationwide routine surveillance open MRS data could be used to inform on patients’ retention and viral load suppression.

Our study also has several limitations. First, the data was collected from an open electronic medical record system for which individual patient-level data were routinely reported. As such, not all desired variables were available – most importantly adherence to HIV medication and outcomes among those lost to care. Second, we could not distinguish reasons for switching to second-line ART other than virological failure. Third, the sampling population only included 340 of the 513 health facilities with second-line patients. Thus, there is a risk of selection bias innate to the data availability. Finally, as with all observational studies, confounding through unmeasured covariates need to be considered when interpreting the reported associations.

Conclusions
In conclusion, our study suggests that patients on second-line ART within Rwanda are doing relatively well, with high levels of retention in care and viral suppression. A better understanding of adherence and adherence interventions for those that are less healthy is required. Importantly, routine viral load measurement and tracing of loss to follow-up is fundamental in resource limited settings in order to minimize the risk of treatment failure.

Abbreviations
AKC: Aikaike Information Criteria; ART: Anti-retroviral therapy; ATV/r: Atazanavir/ritonavir; BMI: Body mass index; CI: Confidence interval; EMR: Electronic medical record; HR: Hazard Ratio; IQR: Interquartile ranges; LTV/r: Lopinavir/ritonavir; NNRTI: Non-nucleoside/nucleotide reverse transcriptase inhibitors; NRTI: Nucleoside/nucleotide reverse transcriptase inhibitors; OR: Odds ratio; PI: Protease Inhibitor; PI/r: Ritonavir-boosted protease inhibitor; PLHIV: People living with HIV; SSA: Sub-Saharan Africa; UNAIDS: Joint United Nations Programme on HIV/AIDS; VL: Viral load; WHO: World Health Organization

Acknowledgments
We are grateful to all programme partners that assisted in the delivery and implementation of HIV services in Rwanda, including the Global Fund to Fight HIV/AIDS, TB, and Malaria; the US President’s Emergency Plan for AIDS Relief (PEPFAR); and the Government of Rwanda. We thank all the health care providers and openMRS programmers for assisting with the onsite extraction of electronic medical records data. We would also like to thank Dr. Vitoria Marco Antonio De Avilla who reviewed an earlier version of this manuscript.

Funding
Not applicable.

Availability of data and materials
The datasets used during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
SN designed the study and had full access to the data. SN undertook full responsibility for the data, accuracy of analysis, and final decision-making for submission. SN and HCB designed the study. SN, DS and VN collected the data. SN, VN, and MS conducted data management. VN, EJM and HCB contributed to the study concept and design. MS, and SK conducted the statistical analysis and SN and ER contributed to statistical analysis. SN, MS, UJP and SK drafted the manuscript. All authors contributed to the acquisition, analysis, or interpretation of data. NF, EJM, MT and HCB critically revised the manuscript. Material support was provided by SN, MS, ER, UJP and VN. HCB supervised the study. All authors have read and approved the manuscript.

Ethics approval and consent to participate
The use of the routine programme data was approved by the Rwanda National Ethics Committee hosted under The Rwanda Ministry of Health which also granted approval for data access and use to the principal investigator (SN). The data presented in this study were accessed directly in the national reporting system thus participants’ consent waiver was obtained from Rwanda Ethics Committee.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Institute of HIV Disease Prevention and Control, Rwanda Biomedical Centre, KG 203 St, Kigali, Rwanda. 2Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, University of Basel, Spitalstrasse 12, 1st
floor, CH-4031 Basel, Switzerland. 1Swiss Tropical and Public Health Institute, University of Basel, Strickmattstrasse 7, 4051 Basel, Switzerland. 2University of Rwanda, School of Medicine and Allied Sciences, RK 737 Street-Gikondo, Kigali, Rwanda. 3Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, Faculty of Health Sciences, University of Cape Town, Observatory 7925, South Africa. 4School of Population and Public Health, University of British Columbia, 2206 East Mall, Vancouver, BC V6T 1Z3, Canada. 5Department of Health Research Methods, Evidence, and Impact, McMaster University, 1280 Main Street, West Hamilton, ON L8S 4K1, Canada.

Received: 3 April 2018 Accepted: 24 March 2019
Published online: 05 April 2019

References
1. UNAIDS (2016). Global aids update report. UNAIDS (2016). Global aids update report.
2. UNAIDS (2016). Get on the Fast-Track. UNAIDS (2016). Global aids update report.
3. Nsanzimana S, Kanters S, Remera E, Forrest JI, Binagwaho A, Condo J, et al. The HIV-1 epidemic: low- to middle-income countries. Cold Spring Harb Perspect Med. 2012;2(3):e271–81.
4. Hobson P, Care P. First-line antiretroviral treatment failure and associated factors in HIV patients at the University of Gondar Teaching Hospital, Gondar, Northwest Ethiopia; 2016. p. 141–6.
5. Shearer K, Evans D, Moyo F, Rohr JK, Berhanu R, Van Den Berg L, et al. Treatment outcomes of over 1000 patients on second-line protease inhibitor-based antiretroviral therapy from four public-sector HIV treatment facilities across Johannesurg, South Africa. Trop Med Int Heal. 2012;17(2):221–31.
6. Assefa Y, Kifle A, Tesfaye D, Mariam DH, Klos H, Edwin W, et al. Outcomes of antiretroviral treatment program in Ethiopia: Retention of patients in care is a major challenge and varies across health facilities. BMC Health Serv Res. 2011;11(1):81.
7. Sherr K, Pfeiffer J, Mussa A, Vio F, Gimbel S, Micek M, et al. The role of nonphysician clinicians in the rapid expansion of HIV Care in Mozambique. JAIDS J Acquir Immune Defic Syndr. 2009;52:S20–3.
8. Bartlett JA, Shao JF. Successes, challenges, and limitations of current antiretroviral therapy in low-income and middle-income countries. Lancet Infect Dis. 2009;9(9):637–49.
9. Shao Y, Williamson C. The HIV-1 epidemic: low- to middle-income countries. Cold Spring Harb Perspect Med. 2012;2(3):a007187.
10. Nsanzimana S, Kanters S, Remera E, Forrest JI, Binagwaho A, Condo J, et al.Articles HIV care continuum in Rwanda: a cross-sectional analysis of the national programme. 2013. p. 208–15.
11. Nsanzimana S, Reepalu A, Balcha TT, Jarso G, Björkman P. Retention in care among HIV-positive patients initiating second-line antiretroviral therapy: a retrospective study from an Ethiopian public hospital clinic. Glob Health Action. 2016;9(1):1–8.
12. Sherr K, Pfeiffer J, Mussa A, Vio F, Gimbel S, Micek M, et al. The role of nonphysician clinicians in the rapid expansion of HIV Care in Mozambique. JAIDS J Acquir Immune Defic Syndr. 2009;52:S20–3.
13. Shao Y, Williamson C. The HIV-1 epidemic: low- to middle-income countries. Cold Spring Harb Perspect Med. 2012;2(3):a007187.
14. Nsanzimana S, Kanters S, Remera E, Forrest JI, Binagwaho A, Condo J, et al. HIV care continuum in Rwanda: a cross-sectional analysis of the national programme. Lancet HIV. 2015;2(7):e271–81.
15. Nsanzimana S, Kanters S, Remera E, Forrest JI, Binagwaho A, Condo J, et al. Outcomes of HIV-positive patients initiating second-line antiretroviral therapy: a retrospective study from an Ethiopian public hospital clinic. Glob Health Action. 2016;9(1):29943.
16. Shearer K, Evans D, Moyo F, Rohr JK, Berhanu R, Van Den Berg L, et al. Treatment outcomes of over 1000 patients on second-line protease inhibitor-based antiretroviral therapy from four public-sector HIV treatment facilities across Johannesburg, South Africa. Trop Med Int Heal. 2012;17(2):221–31.
17. Assefa Y, Kifle A, Tesfaye D, Mariam DH, Klos H, Edwin W, et al. Outcomes of antiretroviral treatment program in Ethiopia: Retention of patients in care is a major challenge and varies across health facilities. BMC Health Serv Res. 2011;11(1):81.
18. d’Amour NJ, Riedel DJ, Mwumwaniza M, Sebuhoro D, Uwimbaabazi JC, Kubwimana M, et al. Drug resistance mutations after the first 12 months on antiretroviral therapy and determinants of virological failure in Rwanda. Trop Med Int Heal. 2012;17(7):928–35.
19. Ajose O, Mookerjeer S, Mills EJ, Boule A, Ford N. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings. AIDS. 2012;26(8):929–38.
20. Boettiger DC, Nguyen VK, Durier N, Bui HV, Heng Sim BL, Azwa I, et al. Efficacy of second-line antiretroviral therapy among people living with HIV/AIDS in Asia. JAIDS J Acquir Immune Defic Syndr. 2015;68(2):186–95.
21. Hosseinipour M, Kumwenda J, Weigel R, Brown L, Mzinganjira D, Mhango B, et al. Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV Med. 2010;11(8):510–8.
22. Win MM, Maek-a-nantawat W, Phonrat B, Kiertiburanakul S, Sungkanuparp S. Virolologic and Immunologic Outcomes of the Second-Line Regimens of Antiretroviral Therapy Among HIV-Infected Patients in Thailand. J Int Assoc Physicians AIDS Care. 2011;10(1):57–63.
23. Wilhelmsen S, Reepalu A, Tolera Balcha T, Jarso G, Björkman P. Retention in care among HIV-positive patients initiating second-line antiretroviral therapy: a retrospective study from an Ethiopian public hospital clinic. Glob Health Action. 2016;9(1):29943.
24. Fox MP, Ires P, Long L, Mathew K, Sanne I. High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. JAIDS J Acquir Immune Defic Syndr. 2015;63(4):S50–6.
25. Kanters S, Socias ME, Paton NI, Worsa M, Doherty M, Ayers D, et al. Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis. Lancet HIV. 2017;4(10):e433–41.
26. Laker E, Mambule T, Nalwanga D, Musaazi J, Kiragga A, Parkes-Ratnesh R. Boosted lopinavir vs boosted atazanavir in patients failing a NNRTI first line regimen in an urban clinic in Kampala. J Int AIDS Soc. 2014;17:19792.
27. Onogbu DM, Lim R, Tsew H, Stanley CC, Tembo P, Broadhurst R, et al. A cross-sectional study to evaluate second-line virological failure and elevated bilirubin as a surrogate for adherence to atazanavir/ritonavir in two urban HIV clinics in Lilongwe. Malawi BMC Infect Dis. 2017;17(1):461.
28. Smith D, Jeganathan S, Ray J. Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations. HIV Clin Trials. 2007;8(1):34–8.
29. Jobanputra K, Parker LA, Ash C, Okello V, Maphalala G, Kershberger B, et al. Factors Associated with Virological Failure and Suppression After Enhanced Adherence Counselling, in Children, Adolescents and Adults on Antiretroviral Therapy for HIV in Swaziland. Paraskevis D, editor. PLoS One. 2015;10(2):e0131644.
30. Johnston V, Fielding KL, Charalambous S, Churchyard G, Phillips A, Grant AD. Outcomes following virological failure and predictors of switching to second-line antiretroviral therapy in a South African treatment program. JAIDS J Acquir Immune Defic Syndr. 2012;61(3):370–80.
31. Wilhelmsen S, Reepalu A, Balcha TT, Jarso G, Bjo P. Retention in care among HIV-positive patients initiating second-line antiretroviral therapy: a retrospective study from an Ethiopian public hospital clinic. Glob Health Action. 2016;9(1):29943.
32. Kyaw NTT, Harries AD, Kumar AM V, Oo MM, Kyaw KKW, Win T, et al. High rate of virological failure and low rate of switching to second-line treatment among adolescents and adults living with HIV on first-line ART in Myanmar, 2005–2015. De Socio GV, editor. PLoS One. 2017;12(2):e0171780.
33. Schoffelen AF, Wensing AMJ, Tempelman HA, Geelen SPM, Hooijen A, Barth RE. Sustained Virological Response on Second-Line Antiretroviral Therapy following Virological Failure in HIV-Infected Patients in Rural South Africa. Suis-Cremer N, editor. PLoS One. 2013;8(3):e58526.
34. Stinson K, Ford N, Cox V, Boule A. Patients lost to care are more likely to be Viremic than patients still in Care. Clin Infect Dis. 2014;58(9):1344–5.
35. d’Amour N, Ndharnama J, Riedel DJ, Mukhayimpundu R, Nsanzimana S, Nyibizi G, Mutagavora E, et al. HIV drug resistance mutations among patients failing second-line antiretroviral therapy in Rwanda. Antivir Ther. 2015;20(3):253–9.
36. Al-Dakkak I, Patel S, McCann E, Gadkari A, Prajapati G, Maisie EM. The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: a systematic review and meta-analysis. AIDS Care. 2013;25(4):400–14.